167 related articles for article (PubMed ID: 24405121)
21. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
22. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
24. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
26. Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins.
Lu B; Li J; Pan J; Huang B; Liu J; Zheng D
Acta Biochim Biophys Sin (Shanghai); 2013 Aug; 45(8):683-91. PubMed ID: 23688587
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
Bar-Natan M; Stroopinsky D; Luptakova K; Coll MD; Apel A; Rajabi H; Pyzer AR; Palmer K; Reagan MR; Nahas MR; Karp Leaf R; Jain S; Arnason J; Ghobrial IM; Anderson KC; Kufe D; Rosenblatt J; Avigan D
Br J Haematol; 2017 Mar; 176(6):929-938. PubMed ID: 28107546
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
[TBL] [Abstract][Full Text] [Related]
29. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antimyeloma effects of zoledronate and simvastatin.
Schmidmaier R; Simsek M; Baumann P; Emmerich B; Meinhardt G
Anticancer Drugs; 2006 Jul; 17(6):621-9. PubMed ID: 16917207
[TBL] [Abstract][Full Text] [Related]
32. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
[TBL] [Abstract][Full Text] [Related]
33. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Kumar S; Raje N; Hideshima T; Ishitsuka K; Roccaro A; Shiraishi N; Hamasaki M; Yasui H; Munshi NC; Richardson P; Figg WD; Anderson KC
Leukemia; 2005 Jul; 19(7):1253-61. PubMed ID: 15858615
[TBL] [Abstract][Full Text] [Related]
34. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
35. Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.
Shen Y; Sun Y; Zhang L; Liu H
Tumour Biol; 2017 Jun; 39(6):1010428317703941. PubMed ID: 28653881
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
37. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics and chemical library screens reveal a novel SCF
Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
[TBL] [Abstract][Full Text] [Related]
39. Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
Kim B; Kim SH; Jeong SJ; Sohn EJ; Jung JH; Lee MH; Kim SH
J Agric Food Chem; 2012 Oct; 60(39):9882-9. PubMed ID: 22967175
[TBL] [Abstract][Full Text] [Related]
40. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
